PeptidePedia The community reference

Contributions of ShortageShona

User contributions·24 logged edits·page 1 of 1

Contributions by ShortageShona, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 8,544 edits includes activity predating the current log.

  1. 10:15, 6 Jul 2026 (diff | hist) Sharps disposal 20,441 ±0 rm the brand-specific instruction; it is not general
  2. 16:46, 16 Jun 2026 (diff | hist) Patent expiry and biosimilars 4,553 ±0 state that research-use-only labelling is a commercial category, not an approval
  3. 17:06, 12 Jun 2026 (diff | hist) ISO 9001 4,278 ±0 correct the description of the research-use-only exemption
  4. 15:27, 14 Feb 2026 (diff | hist) Flourishglobal Peptide Biotech 14,771 +220 state which lines are held in regional stock
  5. 08:18, 11 Feb 2026 (diff | hist) SinoPep 16,798 ±0 add the research-use-only statement to the lead rather than only the footer
  6. 03:54, 15 Dec 2025 (diff | hist) ISO 9001 4,278 ±0 m add the telehealth prescribing point as attributed
  7. 20:07, 12 Dec 2025 (diff | hist) Survodutide 5,445 ±0 state plainly that the research-use-only form is not approved for human use
  8. 00:54, 29 Sep 2025 (diff | hist) Trifluoroacetate counterion 4,865 ±0 give the injection volume, without which the loading cannot be judged
  9. 20:35, 27 Sep 2025 (diff | hist) Reconstitution of lyophilised peptides 5,761 ±0 ce, tighten prose
  10. 06:15, 21 Sep 2025 (diff | hist) GenScript Peptides 6,349 +2,136 add the incorporation year, attributed to the registry record
  11. 23:31, 13 Sep 2025 (diff | hist) Peptide aggregation 5,516 ±0 rm the assertion that two laboratories must agree; they need not
  12. 02:36, 21 Feb 2025 (diff | hist) Prior authorisation 2,250 ±0 m convert the country price comparison to a table with a common currency
  13. 13:29, 4 Feb 2025 (diff | hist) Talk:Research use only 748 +201 /* "Not approved" versus "unapproved" */ reply
  14. 05:32, 26 Jan 2025 (diff | hist) Patent expiry and biosimilars 2,578 ±0 add the patent-expiry statement, attributed and dated
  15. 20:12, 17 Jan 2025 (diff | hist) Good manufacturing practice 3,330 +792 m rm the claim that the position has changed; no source supports it
  16. 14:27, 5 Jan 2025 (diff | hist) Patent expiry and biosimilars 1,842 ±0 add short description
  17. 07:19, 30 Dec 2024 (diff | hist) Peptide stability table 1,664 +252 m fix the arithmetic in the second worked example
  18. 16:25, 19 Dec 2024 (diff | hist) Customs seizure 2,332 +533 clarify that a business licence is not a manufacturing authorisation
  19. 21:15, 12 Dec 2024 (diff | hist) Regulatory status by jurisdiction 2,721 +582 m correct the description of the shortage-list mechanism
  20. 17:59, 2 Dec 2024 (diff | hist) LEADER trial 2,357 ±0 m correct the endpoint hierarchy — that was a secondary endpoint
  21. 05:54, 2 Nov 2024 (diff | hist) ISO 9001 2,449 ±0 rm the advice on importation; the article describes the position and does not advise
  22. 23:49, 16 Sep 2024 (diff | hist) GL Biochem (Shanghai) 6,397 +1,072 label the reception tally as weak, self-selected evidence at this point of use
  23. 05:38, 21 Aug 2024 (diff | hist) Fmoc chemistry 2,620 +670 m expand §The cycle
  24. 19:05, 30 Jun 2024 (diff | hist) Mass spectrometry 2,090 +732 close an unbalanced quotation mark